WO1996026918A1 - Synthesis of carboxylic and hydroxamic acid derivatives - Google Patents
Synthesis of carboxylic and hydroxamic acid derivatives Download PDFInfo
- Publication number
- WO1996026918A1 WO1996026918A1 PCT/GB1996/000467 GB9600467W WO9626918A1 WO 1996026918 A1 WO1996026918 A1 WO 1996026918A1 GB 9600467 W GB9600467 W GB 9600467W WO 9626918 A1 WO9626918 A1 WO 9626918A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- reaction
- residue
- solid phase
- acid
- Prior art date
Links
- 0 CC(C)C[C@](C*)(C(NC(C(C)(C)C)C(NC(C)(C)C)=O)=O)N=C Chemical compound CC(C)C[C@](C*)(C(NC(C(C)(C)C)C(NC(C)(C)C)=O)=O)N=C 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a method for the preparation of hydroxamic acid and carboxylic acid derivatives, particularly biologically active compounds, and especially matrix metalloproteinase inhibitors
- Biologicall y Active Hydroxamic Acid and Carboxylic Acid Derivatives Compounds which have the property of inhibiting the action of metalloprotei ⁇ ases involved in connective tissue breakdown such as collagenase stromeiysin and gelatmase (known as "matrix metalloproteinases", and herein referred to as MMPs) are thought to be potentially useful for the treatment or prophylaxis of conditions involving such tissue breakdown, for example rheumatoid arthritis, osteoarth ⁇ tis, osteopenias such as osteoporosis, pe ⁇ odontitis, gingivitis, comeal epidermal or gastric ulceration, and tumour metastasis, invasion and growth It has been found that hydroxamic acid MMP inhibitors can also inhibit the production of the cytokme tumour necrosis factor (herein referred to as "TNF”) (Mohler et al Nature 1994 370 218-220, Gearing AJH et al , Nature 1994, 370 555-557
- Metalloproteinases are characterised by the presence in the structure of a zinc(ll) ionic site. It is now known that there exists a range of metalloprotei ⁇ ase enzymes that includes fibroblast collagenase (Type 1), PMN-collagenase, 72 kDa-gelatinase, 92 kDa-gelatinase, stromelysin, stromelysin-2 and PUMP-1 (J.F. Woessner, FASEB J, 1991 , 5, 2145-2154). Many known MMP inhibitors are peptide derivatives, based on naturally occuring amino acids, and are analogues of the cleavage site in the collagen molecule. A recent paper by Chapman et al.
- MMP inhibitors are less peptidic in structure, and may more properly be viewed as pseudopeptides or peptide mimetics.
- Such compounds usually have a functional group capable of binding to the zinc (II) site in the MMP, and known classes include those in which the zinc binding group is a hydroxamic acid, carboxylic acid, sulphydryl, and oxygenated phosphorus (eg phosphinic acid and phosphonamidate including aminophosphonic acid) groups.
- MMP inhibitors Two known classes of pseudopeptide or peptide mimetic MMP inhibitors have a hydroxamic acid group and a carboxylic group respectively as their zinc binding groups. With a few exceptions, such known MMPs may be represented by the structural formula (A)
- Z is the zinc binding hydroxamic acid (-CONHOH) or carboxylic acid (-COOH) group and the groups R, to R 4 are variable in accordance with the specific prior art disclosures of such compounds. Examples of patent publications disclosing such structures are given below.
- a key reaction, described in the above patent applications, for the synthesis of the pseudopeptide metalloproteinase inhibitors is the coupling of a carboxylic acid derivative of formula (B) with an amino acid derivative of formula (C)
- This compound (D) is then converted to a compound of general formula (A) by transformation of the group Z to a zinc binding group Z as defined for general formula (A).
- a disadvantage of this route is that the preparation of the amino acid derivative (C) usually involves a number of steps, particularly when it is an unnatural amino acid derivative, as is often desirable. There is therefore a need for alternative methods for the preparation of hydroxamic acid and carboxylic acid based compounds of type (A).
- Solid phase synthesis is an established and effective method for the preparation of peptides, and offers advantages over conventional solution phase chemistry in terms of purification and simplicity (Atherton E, Sheppard RC, Solid Phase Peptide Synthesis: A Practical Approach; IRL Press at Oxford University Press: Oxford, 1989). Solid phase synthesis may also be used for the preparation of non-peptide molecules (Leznoff CC, Ace. Chem. Res. , 1978. 11 , 327-333) and recently there has been considerable interest in the application of this methodology to the synthesis of combinatorial libraries for biologically active lead compound optimisation and discovery (Moos WH et al., Annu. Rep. Med. Chem., 1993, 28. 315-324).
- Solid phase synthesis requires an appropriate solid substrate which carries a plurality of functional groups to which the first reactive entity in the proposed synthesis may be covalently coupled, and from which the desired molecule may be cleaved after assembly.
- the solid substrate should be compatible with the solvents and reaction conditions that are to be used in the peptide or non-peptide synthesis.
- the final step in solid phase synthesis is the cleavage of the covalent bond between the desired peptide or non-peptide molecule and the linker. It is desirable that the conditions for the cleavage are orthogonal to those used during the reactions employed for the synthesis of the peptide or non-peptide on the solid support such that undesired cleavage does not occur during the synthesis. Furthermore, the conditions for cleavage should be relatively mild such that they do not result in degradation of the desired peptide or non-peptide.
- Solid substrates which present hydroxyl groups as the points of attachment for the first stage of the synthesis are commonly used, for example substrates which present hydroxyl groups as derivatives of benzyl alcohol, the peptide or non-peptide being attached as a benzyl ester and cleaved by hydrolysis, acidolysis or aminolysis to release the peptide or non-peptide as a carboxylic acid, carboxylate ester or as a carboxamide
- substrates which present ammo groups for example as derivatives of diphenylmethylamine, the peptide or non-peptide being attached as a carboxamide and cleaved by acidolysis to release the peptide or non-peptide as a carboxamide
- substitution of such linkers by a nitro group can enable the photolytic cleavage of the peptides or non-peptides from the residue of the solid substrate
- the Ugi reaction might provide an alternative route for the synthesis of pseudopeptide metalloproteinase inhibitors which could avoid the separate multi-step preparation of the ammo acid derivative (C)
- the Ugi reaction is a four component condensation reaction between a carboxylic acid, an amine, an aldehyde and an isonitnle that proceeds to give an am o acid amide derivative (I.
- the invention is based on the finding that compounds of type (D) which are protected precursors of compounds of structural type (A) may indeed be conveniently synthesised by application of Ugi reaction conditions, in solution or with one of the components attached to a solid phase support, for subsequent deprotection to provide the desired compounds of type (A)
- the present invention provides a method for the preparation of a compound of formula (I)
- X is hydrogen or an ammo protecting group, or the residue of a solid phase reaction substrate
- Y is (i) a group -C0 2 R 5 wherein R 5 is a carboxyl protecting group or the residue of a solid phase reaction substrate or (u) a group -CONR 6 OR 7 wherein R 6 is an ammo protecting group or the residue of a solid phase reaction substrate and R- is a hydroxyl protecting group or the residue of a solid phase reaction substrate, and
- [S,], [S 2 ], [S 3 ] and [S 4 ] each represent covalently bound moieties which are substantially non reactive with the reaction components (II), (III), or (IV) defined below,
- ammo protecting group means a group which may be used for the protection, i e temporary blocking, of ammo nitrogen functionality
- Such groups are widely known, for example from the art of peptide synthesis, and are discussed in the widely used handbook by T W Greene and P G M Wuts, Protective Groups in Organic Synthesis. 2nd Edition, Wiley, New York, 1991
- Specific examples of ammo protecting groups include allyl and benzyl or benzyl optionally substituted in the phenyl ring by one or more nitro or methoxy substituents, for example 4-methoxybenzyl or 2,4-d ⁇ methoxybenzyl
- carboxylic acid protecting group means a group which may be used for the protection, i e temporary blocking, of the oxygen functionality within a carboxylic acid
- such groups are widely known, for example from the art of peptide synthesis, and are discussed in the widely used handbook by T.W Greene and P G M Wuts, Protective Groups in Organic Synthesis, 2nd Edition, Wiley, New York, 1991.
- Specific examples of carboxyl protecting groups include allyl, t-butyl, and benzyl or benzyl optionally substituted in the phenyl ring by one or more ⁇ itro or methoxy substituents, for example 4-methoxybenzyl or 2,4- dimethoxybenzyl.
- hydroxyl protecting group means a group which may be used for the protection, i.e. temporary blocking, of the oxygen functionality of the hydroxyl group.
- groups are widely known, for example from the art of peptide synthesis, and are discussed in the widely used handbook by T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2nd Edition. Wiley, New York. 1991.
- Specific examples of hydroxyl protecting groups include allyl.
- the imine reaction component (III) may be added to the reaction medium together with the carboxylic acid and isonitrile reaction components. It may also be pre ⁇ formed by the condensation of an aldehyde of formula (IIIA) and an amine of formula (IIIB):
- the imine reaction component (III) may be formed in situ by the condensation of an aldehyde of formula (IIIA) and an amine of formula (IIIB) as defined above
- the method of the invention comprises causing the co-condensation in a liquid organic medium of four reaction components, namely the carboxylic acid reaction component of formula (II) above, the aldehyde reaction component of formula (IIIA) above, the amine reaction component of formula (IIIB) above, and the isonitrile reaction component of formula (IV) above, moieties [S,], [S 2 ], [S 3 ] and [S 4 ] being substantially non reactive with these reaction components
- the three- or four-component co-condensation method of the invention may be conducted in a protic solvent such as methanol or 2,2,2-tr ⁇ fluoroethanol, in an aprotic solvent (e g. tetrahydrofuran, chloroform, methylene chloride or acetonitnle) or in a mixed protic/aprotic solvent system
- a protic solvent e g. tetrahydrofuran, chloroform, methylene chloride or acetonitnle
- Methanol is the presently preferred reaction medium, but selection of appropriate organic liquid media for specific combinations of reaction components is a matter of routine
- the reaction components are added to the chosen liquid reaction medium and caused to co-react
- the subsequent co-condensation of carboxylic acid, imine and isonitrile components may proceed in higher yield if conducted in an aprotic solvent (e g tetrahydrofuran) in the presence of a Lewis acid catalyst (e g z ⁇ n
- the co-condensation may be carried out with all reaction components in solution in the organic liquid medium, or with the carboxylic acid component (II) covalently bound to the residue of a solid phase reaction substrate, and the remaining components in solution, or with the imine component (III) covalently bound to the residue of a solid phase reaction substrate, and the remaining components in solution, or with the ammo group of component (IIIB) covalently bound to the residue of a solid phase reaction substrate, and the remaining components in solution
- reaction of a solid substrate refers to a solid base substrate which is substantially insoluble in aqueous or organic reaction media and which is directly, or indirectly through suitable linker groups linked to the relevant N or O atom by a covalent bond which is cleavable by acid hydrolysis or by photolysis
- Base substrates include those known in the art of solid phase peptide synthesis (see for example those described in Stewart JM and Young JD, Solid Phase Peptide Synthesis, 2nd Ed Pierce Chemical Company Rockford Illinois 1984) They include inorganic substrates, for example kieselguhr silica gel and controlled pore glass and polymeric organic substrates for example polystyrene polypropylene polyethylene glycol polyacrylamide cellulose as well as composite inorganic/polymeric substrates such as polyacrylamide supported within a matrix of kieselguhr particles Known base substrates also include ammo and hydroxy functionalised solid substrates, i ⁇ those which are chemically modified by introduction of ammo or hydroxyl groups, to serve as convenient points for further chemical manipulation Examples of particular ammo or hydroxy functionalised solid supports are hydroxymethyl polystyrene, benzhydrylamme polystyrene ("BHA Resin '), methyl benzhydrylamme polystyrene (“MBHA Resin '), polyethylene glycol poly
- hydroxyl- or am o- carrying linker groups can be introduced onto amino and hydroxy functionalised solid substrates, the linker group having characteristics which facilitate the cleavage of the desired synthesised molecule from the solid support.
- the hydroxyl or amino groups presented by the linker groups serve as points for attachment of the first reactive entity in the proposed synthesis.
- the first amino acid of the peptide to be constructed may be attached as an ester formed between the linker-presented hydroxyl group and the carboxyl group of the amino acid.
- the first amino acid of the peptide to be constructed may be attached as a carboxamide formed between the linker-presented amino group and the carboxyl group of the amino acid.
- a solid support resin presenting amino groups on linker groups attached to the base substrate is the resin 5-(4'-aminomethyl-3',5'-dimethoxyphenoxy)-(N-4- methylbenzhydryl)pentyramide-copoly(styrene-1 %-divinylbenzene) resin which has the structure
- P represents the copolystyrene divinylbenzene polymer backbone.
- the carboxylic reaction component (II) may, for example, be attached to hydroxy groups presented by a solid base substrate as a carboxylic ester, or to amino groups presented by a solid base substrate as a N- alkoxycarboxamide; or the imine reaction component (III) may, for example, be formed on the amino groups presented by a solid base substrate, by reaction of such amine groups with the aldehyde component (IIIA); or
- the amine reaction component (IIIB) may be a solid base substrate which presents amino groups.
- Z 1 represents -OH, -NH 2 or -ONH 2 ;
- R 8 represents hydrogen, C C 6 alkyl, or phenyl optionally substituted by one or more substituents selected from C r C 6 alkyl, C r C 6 alkoxy, halogen, nitrile or N0 2 ;
- R 9 and R 10 independently represent hydrogen, C,-C 6 alkyl, C,-C 6 alkoxy, halogen, nitriie or N0 2 ;
- R réelle represents a group -(X 1 ) q -Y 1 - wherein q is 0 or 1
- Another class of linker groups has formula (VA):
- Z 1 R 8 R 9 and R 10 are as defined in formula (V), R 8A is as defined for R e in formula (V), and R 11A is a bond or is as defined for R., in formula (V).
- the product of the method of the invention is a compound of formula (I) defined above.
- product (I) may be further treated, in one or several steps, before or after isolation from the reaction medium, to remove any amine protecting group X, or any amine protecting group, carboxyl protecting group or hydroxyl protecting group present in group Y (or indeed in moieties [S,], [S 2 ], [S 3 ] and [S 4 ]), and, in the case where one of X, R 5 , R 6 and R 7 is the residue of a solid phase reaction substrate, to cleave the covalent bond between that substrate and the relevant N atom of X or N or O atom of Y.
- the product has the structure (IA):
- Trimethylacetaldehyde (0.56 ml, 5.17 mmol) was added to a stirred solution of 2,4- dimethoxybenzylamine hydrochloride (0.86 g, 5.17 mmol) and triethylamme (0.72 ml, 5.17 mmol) in methanol (30 ml) at room temperature.
- benzyl isocyanide (0.97 ml, 5.17 mmol) followed by 2R-(2-methylpropyl)succinic acid-4-t-butyl ester (1.19 g, 5.17 mmol). The mixture was stirred for 2 h and concentrated under reduced pressure to give a pale yellow wax.
- 2,4-D ⁇ methoxybenzylam ⁇ ne hydrochloride (1.68 g, 10.03 mmol) was dissolved in dry methanol containing activated 4A molecular sieves, triethylamme (1 4 ml, 10.03 mmol) and 1-methylcyclopropylaldehyde (1.2 ml, 10.94 mmol) and the mixture stirred in an ice bath for 0.5 h. To this solution was added benzyl isocyanide (1 2 ml.
- Trimethylacetaldehyde (0.24 ml, 2.17 mmol) was added to a stirred 0.2M solution of ammonia in methanol (21.7 ml, 4.34 mmol) at room temperature After 10 mm, t- butyl isocyanide (0.25 ml, 2.17 mmol) was added followed by 2R-(2- methylpropyl)succinic acid-4-t-butyl ester (0.50 g, 2 17 mmol) The mixture was stirred overnight and concentrated under reduced pressure to give t-butyl 3R-[2,2- d ⁇ methyl-1S,R-(t-butylcarbamoyl)propyl-carbamoyl]-5-methylhexanoate as an amorphous white solid (0.49 g, 57%).
- Example 4 as set out in Array 1 below were prepared following an analogous procedure to that employed above for the synthesis of the compound of Example 3 using the appropriate 2-(subst ⁇ tuted)succ ⁇ n ⁇ c ac ⁇ d-4-t-butyl ester derivative in lieu of 2R-(2-methylpropyl)succ ⁇ nic ac ⁇ d-4-t-butyl ester, trimethylacetaldehyde and an isonitrile chosen from n-butyl isocyanide, isopropyl isocyanide, t-butyl isocyanide or cyclohexyl isocyanide.
- Trimethylacetaldehyde (0.12 ml, 1.10 mmol) was added to a stirred 0.2M solution of ammonia in methanol (5.5 ml, 1.10 mmol) at room temperature under argon. After 1 h, t-butyl isocyanide (0.12 ml, 1.10 mmol) was added followed by 2R-(2,2-dimethyl- 4-0X0-1 , 3-dioxalan-5S-yl)-4-methylpentanoic acid (prepared as described in patent application WO 94/02446) (0.31 g, 1.10 mmol). The mixture was stirred for 48 h and concentrated under reduced pressure.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8526105A JPH11501025A (en) | 1995-03-01 | 1996-03-01 | Synthesis of derivatives of carboxylic and hydroxamic acids |
EP96904207A EP0812312A1 (en) | 1995-03-01 | 1996-03-01 | Synthesis of carboxylic and hydroxamic acid derivatives |
US08/894,842 US5849951A (en) | 1995-03-01 | 1996-03-01 | Synthesis of carboxylic and hydroxamic acid derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9504084.6 | 1995-03-01 | ||
GBGB9504084.6A GB9504084D0 (en) | 1995-03-01 | 1995-03-01 | Synthesis of carboxylic and hydroxamic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996026918A1 true WO1996026918A1 (en) | 1996-09-06 |
Family
ID=10770437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1996/000467 WO1996026918A1 (en) | 1995-03-01 | 1996-03-01 | Synthesis of carboxylic and hydroxamic acid derivatives |
Country Status (5)
Country | Link |
---|---|
US (1) | US5849951A (en) |
EP (1) | EP0812312A1 (en) |
JP (1) | JPH11501025A (en) |
GB (2) | GB9504084D0 (en) |
WO (1) | WO1996026918A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997026257A1 (en) * | 1996-01-17 | 1997-07-24 | Smithkline Beecham Plc | Hydroxamic acid based collagenase inhibitors |
WO1998024760A1 (en) * | 1996-12-03 | 1998-06-11 | Graybill Todd L | Aminobenzenedicarboxylic acid-based combinatorial libraries |
US5840974A (en) * | 1996-12-04 | 1998-11-24 | Britisch Biotech Pharmaceuticals, Ltd. | Metalloproteinase inhibitors |
WO1999057097A2 (en) * | 1998-05-06 | 1999-11-11 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
WO1999061655A1 (en) * | 1998-05-29 | 1999-12-02 | Hawaii Biotechnology Group, Inc. | Transition state binding assay |
JP2001055327A (en) * | 1999-06-11 | 2001-02-27 | Fuji Chemical Industries Ltd | New medicine containing hydroxamic acid derivative |
US6541276B2 (en) | 1996-10-28 | 2003-04-01 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives and combinatorial libraries thereof |
WO2004099124A2 (en) * | 2003-05-08 | 2004-11-18 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Novel bioisosteres of actinonin |
US6987104B2 (en) | 2001-06-15 | 2006-01-17 | Vicuron Pharmaceuticals Inc. | Pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use |
US7148242B2 (en) | 2001-06-15 | 2006-12-12 | Novartis Ag | N-formyl hydroxylamine compounds, compositions and methods of use |
WO2008057856A3 (en) * | 2006-11-01 | 2008-12-24 | Bristol Myers Squibb Co | Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5984929A (en) * | 1997-08-29 | 1999-11-16 | Target Therapeutics, Inc. | Fast detaching electronically isolated implant |
US6297337B1 (en) | 1999-05-19 | 2001-10-02 | Pmd Holdings Corp. | Bioadhesive polymer compositions |
US6797820B2 (en) * | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
AU2002315001A1 (en) * | 2001-06-08 | 2002-12-23 | Metaphore Pharmaceuticals, Inc. | Libraries of conformationally constrained peptides, chiral azacrowns, and peptidomimetics and methods of making the same |
US20050255230A1 (en) * | 2004-05-17 | 2005-11-17 | Clerc Claude O | Method of manufacturing a covered stent |
CN102264694B (en) | 2008-10-15 | 2015-11-25 | 基因里克斯(英国)有限公司 | For the preparation of the method for Vorinostat |
WO2010061219A2 (en) | 2008-11-26 | 2010-06-03 | Generics [Uk] Limited | Polymorphs |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0498665A1 (en) * | 1991-02-07 | 1992-08-12 | British Biotech Pharmaceuticals Limited | Hydroxamic acids derivatives, process for their preparation and use thereof |
WO1995002566A1 (en) * | 1993-07-16 | 1995-01-26 | Ontogen Corporation | Synthesis of combinatorial arrays of organic compounds through the use of multiple component combinatorial array syntheses |
-
1995
- 1995-03-01 GB GBGB9504084.6A patent/GB9504084D0/en active Pending
-
1996
- 1996-03-01 WO PCT/GB1996/000467 patent/WO1996026918A1/en not_active Application Discontinuation
- 1996-03-01 US US08/894,842 patent/US5849951A/en not_active Expired - Fee Related
- 1996-03-01 EP EP96904207A patent/EP0812312A1/en not_active Ceased
- 1996-03-01 JP JP8526105A patent/JPH11501025A/en active Pending
- 1996-03-01 GB GB9604512A patent/GB2298423B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0498665A1 (en) * | 1991-02-07 | 1992-08-12 | British Biotech Pharmaceuticals Limited | Hydroxamic acids derivatives, process for their preparation and use thereof |
WO1995002566A1 (en) * | 1993-07-16 | 1995-01-26 | Ontogen Corporation | Synthesis of combinatorial arrays of organic compounds through the use of multiple component combinatorial array syntheses |
Non-Patent Citations (2)
Title |
---|
I. UGI: "From Isocyanides via Four-Component Condensation to Antibiotic Syntheses.", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION IN ENGLISH, vol. 21, no. 11, November 1982 (1982-11-01), WEINHEIM, DE, pages 810 - 9, XP002005383 * |
M. WAKI ET. AL.: "Peptide Synthesis Using the Four-Component Condensation (Ugi Reaction).", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 99, no. 18, 31 August 1977 (1977-08-31), WASHINGTON DC, US, pages 6075 - 82, XP002005382 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997026257A1 (en) * | 1996-01-17 | 1997-07-24 | Smithkline Beecham Plc | Hydroxamic acid based collagenase inhibitors |
US6281245B1 (en) | 1996-10-28 | 2001-08-28 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
US6541276B2 (en) | 1996-10-28 | 2003-04-01 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives and combinatorial libraries thereof |
WO1998024760A1 (en) * | 1996-12-03 | 1998-06-11 | Graybill Todd L | Aminobenzenedicarboxylic acid-based combinatorial libraries |
US6127191A (en) * | 1996-12-03 | 2000-10-03 | 3-Dimensional Pharmaceuticals, Inc. | Aminobenzenedicarboxylic acid-based combinatorial libraries |
US5840974A (en) * | 1996-12-04 | 1998-11-24 | Britisch Biotech Pharmaceuticals, Ltd. | Metalloproteinase inhibitors |
WO1999057097A2 (en) * | 1998-05-06 | 1999-11-11 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
WO1999057097A3 (en) * | 1998-05-06 | 2000-03-09 | Versicor Inc | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
WO1999061655A1 (en) * | 1998-05-29 | 1999-12-02 | Hawaii Biotechnology Group, Inc. | Transition state binding assay |
US6569636B2 (en) | 1998-05-29 | 2003-05-27 | Hawaii Biotechnology Group, Inc. | Assay for modulators of metallo-enzyme activity |
JP2001055327A (en) * | 1999-06-11 | 2001-02-27 | Fuji Chemical Industries Ltd | New medicine containing hydroxamic acid derivative |
US6987104B2 (en) | 2001-06-15 | 2006-01-17 | Vicuron Pharmaceuticals Inc. | Pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use |
US7148242B2 (en) | 2001-06-15 | 2006-12-12 | Novartis Ag | N-formyl hydroxylamine compounds, compositions and methods of use |
US7612059B2 (en) | 2001-06-15 | 2009-11-03 | Vicuron Pharmaceuticals, Inc. | Pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use |
WO2004099124A2 (en) * | 2003-05-08 | 2004-11-18 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Novel bioisosteres of actinonin |
WO2004099124A3 (en) * | 2003-05-08 | 2005-01-20 | Morphochem Ag Komb Chemie | Novel bioisosteres of actinonin |
US7504436B2 (en) * | 2003-05-08 | 2009-03-17 | Novartis Ag | Bioisosteres of actinonin |
WO2008057856A3 (en) * | 2006-11-01 | 2008-12-24 | Bristol Myers Squibb Co | Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
US8067447B2 (en) | 2006-11-01 | 2011-11-29 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
Also Published As
Publication number | Publication date |
---|---|
US5849951A (en) | 1998-12-15 |
GB9604512D0 (en) | 1996-05-01 |
GB9504084D0 (en) | 1995-04-19 |
GB2298423B (en) | 1998-10-21 |
JPH11501025A (en) | 1999-01-26 |
GB2298423A (en) | 1996-09-04 |
EP0812312A1 (en) | 1997-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5849951A (en) | Synthesis of carboxylic and hydroxamic acid derivatives | |
EP0811019B1 (en) | Synthesis of hydroxamic acid derivatives | |
KR20190033516A (en) | New xanthine protector | |
CN111491941B (en) | Novel alkyl diphenyl methane protective agent | |
KR20120128667A (en) | A process for the preparation of lacosamide | |
MXPA03003483A (en) | Process for the preparation of acylphenylalanines. | |
EP0950045B1 (en) | A solid-phase technology for the preparation of amides | |
US5917090A (en) | Matrix metalloproteinase inhibitors | |
EP0835240B1 (en) | Matrix metalloproteinase inhibitors | |
US9732049B2 (en) | Process for preparing 2,4-diamino-3-hydroxybutyric acid derivatives | |
CA1277993C (en) | N2-(1-carboxy-3-oxo-3-phenylpropyl)-l-lysine compounds and their derivatives | |
EP0874799B1 (en) | Preparation of allyl succinate derivatives and starting materials therefor | |
WO2013179297A1 (en) | Process for preparation of (1s, 3s, 5s)-2-[(2s)-2-amino-2-(3-hydroxy-1-adamantyl) acetyl]-2-azabicyclo [3.1.0] hexane-3-carbonitrile | |
WO1997003966A1 (en) | N-(amino acid) substituted succinic acid amide derivatives as metalloproteinase inhibitors | |
EP1243576A1 (en) | Processes for producing (aminomethyl)trifluorocarbinol derivatives | |
JP5704763B2 (en) | Production of trans-4-aminocyclopent-2-ene-1-carboxylic acid derivative | |
JPH0717940A (en) | Carbamate group-containing ester | |
EP1651627A2 (en) | Process for preparation of oxetan-2-ones | |
JP2003064064A (en) | Method for producing amidothiazole derivative ester compound | |
US4904802A (en) | Imides | |
US20230174569A1 (en) | PROCESS PER PREPARING (3a,5a)-20-OXOPREGNAN-3-YL GLYCYL-L-VALINATE HYDROCHLORIDE | |
Voynikov et al. | Novel Leucine Derived Amides of Theophylline-7-acetic Acid | |
EP0468643A1 (en) | Process for the preparation of acrylates | |
JPH0778038B2 (en) | Process for producing L-argininal di-lower alkyl acetal | |
JP2004515481A (en) | Quaternary amino acids on solid support |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996904207 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1996 526105 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08894842 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1996904207 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1996904207 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996904207 Country of ref document: EP |